Hernix 40mg (neratinib)


Product Description:

Hernix (neratinib)
Neratinib is an oral, irreversible tyrosine kinase inhibitor. It is the only product in the world approved for intensive adjuvant therapy after treatment with HER2-positive breast cancer with trastuzumab (Herceptin) to reduce the risk of recurrence. The applicable population is to complete the standard trastuzumab adjuvant treatment of patients with undeveloped disease but high-risk factors.
For breast cancer patients who have completed standard trastuzumab (Herceptin, Herceptin) adjuvant therapy, disease progression, but high-risk factors

Product Features:

Product Name: Hernix
Generic Name: Neratinib
Formulation: Tablet
medicine Pack Size: 180’s
Available Strengths : 40 mg
Categories: irreversible tyrosine kinase inhibitor
Manufacturer: Beacon Pharmaceuticals Ltd.


There are no reviews yet.

Be the first to review “Hernix 40mg (neratinib)”

Your email address will not be published.